• Je něco špatně v tomto záznamu ?

Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma

R. Vendramin, V. Katopodi, S. Cinque, A. Konnova, Z. Knezevic, S. Adnane, Y. Verheyden, P. Karras, E. Demesmaeker, FM. Bosisio, L. Kucera, J. Rozman, I. Gladwyn-Ng, L. Rizzotto, E. Dassi, S. Millevoi, O. Bechter, JC. Marine, E. Leucci

. 2021 ; 218 (9) : . [pub] 20210721

Jazyk angličtina Země Spojené státy americké

Typ dokumentu kazuistiky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003766

The ability to adapt to environmental stress, including therapeutic insult, contributes to tumor evolution and drug resistance. In suboptimal conditions, the integrated stress response (ISR) promotes survival by dampening cytosolic translation. We show that ISR-dependent survival also relies on a concomitant up-regulation of mitochondrial protein synthesis, a vulnerability that can be exploited using mitoribosome-targeting antibiotics. Accordingly, such agents sensitized to MAPK inhibition, thus preventing the development of resistance in BRAFV600E melanoma models. Additionally, this treatment compromised the growth of melanomas that exhibited elevated ISR activity and resistance to both immunotherapy and targeted therapy. In keeping with this, pharmacological inactivation of ISR, or silencing of ATF4, rescued the antitumoral response to the tetracyclines. Moreover, a melanoma patient exposed to doxycycline experienced complete and long-lasting response of a treatment-resistant lesion. Our study indicates that the repurposing of mitoribosome-targeting antibiotics offers a rational salvage strategy for targeted therapy in BRAF mutant melanoma and a therapeutic option for NRAS-driven and immunotherapy-resistant tumors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003766
003      
CZ-PrNML
005      
20220127145902.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1084/jem.20210571 $2 doi
035    __
$a (PubMed)34287642
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vendramin, Roberto $u Laboratory for RNA Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium
245    10
$a Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma / $c R. Vendramin, V. Katopodi, S. Cinque, A. Konnova, Z. Knezevic, S. Adnane, Y. Verheyden, P. Karras, E. Demesmaeker, FM. Bosisio, L. Kucera, J. Rozman, I. Gladwyn-Ng, L. Rizzotto, E. Dassi, S. Millevoi, O. Bechter, JC. Marine, E. Leucci
520    9_
$a The ability to adapt to environmental stress, including therapeutic insult, contributes to tumor evolution and drug resistance. In suboptimal conditions, the integrated stress response (ISR) promotes survival by dampening cytosolic translation. We show that ISR-dependent survival also relies on a concomitant up-regulation of mitochondrial protein synthesis, a vulnerability that can be exploited using mitoribosome-targeting antibiotics. Accordingly, such agents sensitized to MAPK inhibition, thus preventing the development of resistance in BRAFV600E melanoma models. Additionally, this treatment compromised the growth of melanomas that exhibited elevated ISR activity and resistance to both immunotherapy and targeted therapy. In keeping with this, pharmacological inactivation of ISR, or silencing of ATF4, rescued the antitumoral response to the tetracyclines. Moreover, a melanoma patient exposed to doxycycline experienced complete and long-lasting response of a treatment-resistant lesion. Our study indicates that the repurposing of mitoribosome-targeting antibiotics offers a rational salvage strategy for targeted therapy in BRAF mutant melanoma and a therapeutic option for NRAS-driven and immunotherapy-resistant tumors.
650    _2
$a senioři $7 D000368
650    _2
$a zvířata $7 D000818
650    _2
$a antibiotika antitumorózní $x farmakologie $7 D000903
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a doxycyklin $x farmakologie $7 D004318
650    _2
$a chemorezistence $x účinky léků $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melanom $x farmakoterapie $x genetika $x mortalita $x patologie $7 D008545
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši nahé $7 D008819
650    _2
$a mitochondriální ribozomy $x účinky léků $7 D000069396
650    _2
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    _2
$a fyziologický stres $x účinky léků $7 D013312
650    _2
$a tigecyklin $x farmakologie $7 D000078304
650    _2
$a nádory uvey $x farmakoterapie $x patologie $7 D014604
650    _2
$a xenogenní modely - testy antitumorózní aktivity $7 D023041
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Katopodi, Vicky $u Laboratory for RNA Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium
700    1_
$a Cinque, Sonia $u Laboratory for RNA Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium
700    1_
$a Konnova, Angelina $u Laboratory for RNA Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium
700    1_
$a Knezevic, Zorica $u Laboratory for RNA Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium
700    1_
$a Adnane, Sara $u Laboratory for RNA Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium
700    1_
$a Verheyden, Yvessa $u Laboratory for RNA Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium
700    1_
$a Karras, Panagiotis $u Laboratory for Molecular Cancer Biology, Center for Cancer Biology, Vlaams Instituut voor Biotechnologie, Leuven, Belgium $u Department of Oncology, Laboratory for Molecular Cancer Biology, Katholieke Universiteit Leuven, Belgium
700    1_
$a Demesmaeker, Ewout $u Laboratory for RNA Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium
700    1_
$a Bosisio, Francesca M $u Translational Cell and Tissue Research, Katholieke Universiteit Leuven, Belgium
700    1_
$a Kucera, Lukas $u Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic
700    1_
$a Rozman, Jan $u Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic
700    1_
$a Gladwyn-Ng, Ivan $u Taconic Biosciences, Leverkusen, Germany
700    1_
$a Rizzotto, Lara $u Trace, Leuven Cancer Institute, Katholieke Universiteit Leuven, Belgium
700    1_
$a Dassi, Erik $u Laboratory of RNA Regulatory Networks, Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy
700    1_
$a Millevoi, Stefania $u Cancer Research Centre of Toulouse, Institut national de la santé et de la recherche médicale Joint Research Unit 1037, Toulouse, France $u Université Toulouse III Paul Sabatier, Toulouse, France $u Laboratoire d'Excellence "TOUCAN," Toulouse, France
700    1_
$a Bechter, Oliver $u Department of General Medical Oncology, Leuven Cancer Institute, Universitair Ziekenhuis Leuven, Leuven, Belgium
700    1_
$a Marine, Jean-Christophe $u Laboratory for Molecular Cancer Biology, Center for Cancer Biology, Vlaams Instituut voor Biotechnologie, Leuven, Belgium $u Department of Oncology, Laboratory for Molecular Cancer Biology, Katholieke Universiteit Leuven, Belgium
700    1_
$a Leucci, Eleonora $u Laboratory for RNA Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium $u Trace, Leuven Cancer Institute, Katholieke Universiteit Leuven, Belgium
773    0_
$w MED00002668 $t The Journal of experimental medicine $x 1540-9538 $g Roč. 218, č. 9 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34287642 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145859 $b ABA008
999    __
$a ok $b bmc $g 1751274 $s 1154915
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 218 $c 9 $e 20210721 $i 1540-9538 $m The Journal of experimental medicine $n J Exp Med $x MED00002668
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace